1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ARCHIVE
ARCHIVE
- CORPORATE ROUNDUP
July 23, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -2-
July 23, 2001
- BUSINESS NEWS IN BRIEF -2-
July 23, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
July 23, 2001
- BUSINESS NEWS IN BRIEF -1-
July 23, 2001
- Compact, Inexpensive Accelerators Necessary: Monkasho Survey
July 23, 2001
- Only 16% of Citizens Use Life-style Improving Drugs: Survey
July 23, 2001
- Kyowa Hakko to Start Marketing Cholesterol-lowering Super Soy in the US, Europe
July 23, 2001
- High-concentration Morphine HCl Preparations to Be Launched by 5 Companies
July 23, 2001
- Pharmacia to Launch Nicorette as OTC Drug in Fall
July 23, 2001
- Shionogi Grants the Rights to BNP Assay to Bayer Corp.
July 23, 2001
- Tsuruha: Sales Up 19.5%, Net Profits Up 8.2%
July 23, 2001
- Oriental Yeast Expands Collaboration with Lexicon Genetics
July 23, 2001
- SSP Wants to Become No. 1 OTC Drug Maker
July 23, 2001
- Suzuken Aims to Become No.1 Wholesaler in 2010
July 23, 2001
- Boots-MC to Be Dissolved
July 23, 2001
- Mochida Licenses Immune Response Modifier from 3M
July 23, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -1-
July 23, 2001
- Taisho, GSK to Jointly Develop Smoking Cessation Aid
July 23, 2001
- Enhancing Competitiveness of Japanese Makers Discussed: OPIR Report
July 23, 2001
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…